Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading Volume - Time to Buy?

Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 296,481 shares changed hands during trading, an increase of 310% from the previous session's volume of 72,357 shares.The stock last traded at $24.93 and had previously closed at $25.12.

Analysts Set New Price Targets

PHVS has been the topic of a number of recent research reports. Wedbush reaffirmed an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th. Cantor Fitzgerald reduced their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a report on Wednesday, May 14th. Finally, Guggenheim initiated coverage on Pharvaris in a report on Wednesday, June 11th. They issued a "buy" rating and a $32.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Pharvaris has an average rating of "Buy" and a consensus target price of $36.20.

Pharvaris Stock Performance

The firm's 50-day simple moving average is $17.26 and its 200 day simple moving average is $16.67. The company has a market cap of $1.31 billion, a P/E ratio of -8.30 and a beta of -2.82.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). As a group, research analysts forecast that Pharvaris N.V. will post -2.71 earnings per share for the current year.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently modified their holdings of the business. JPMorgan Chase & Co. lifted its stake in Pharvaris by 1,125.3% in the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock valued at $59,000 after purchasing an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Pharvaris in the 4th quarter valued at about $64,000. KLP Kapitalforvaltning AS acquired a new stake in Pharvaris in the 4th quarter valued at about $111,000. Point72 Asset Management L.P. acquired a new stake in Pharvaris in the 4th quarter valued at about $152,000. Finally, Legal & General Group Plc lifted its stake in Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after purchasing an additional 994 shares during the last quarter.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.